NewsBenzingaMoleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Benzinga 2026.10.30 12:43 (GMT+0) Open on Benzinga Other news DeepSeek Harness Discloses for the First Time: Daily Active Users Exceed 1.5 Million, Adding Over 1 Million in One Month AI Company Thinking Machines Lab Raising $5B at $40B Pre-Money Valuation Binance to Gradually Open Withdrawals for More Assets Starting 12:00 on November 6 Tsinghua Graduate Scammed for 45 Days While Studying in London, Induced to Buy Crypto and Transfer Funds US SOL spot ETFs record single-day total net outflow of $1.1761 million MAS Responds to Binance Incident: Reminds Public Not to Deal with Unregulated Companies
DeepSeek Harness Discloses for the First Time: Daily Active Users Exceed 1.5 Million, Adding Over 1 Million in One Month
Tsinghua Graduate Scammed for 45 Days While Studying in London, Induced to Buy Crypto and Transfer Funds
